Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
Moodys
Chinese Patent Office
Johnson and Johnson
Chubb
Citi
Colorcon
US Army
Queensland Health

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,689,761

« Back to Dashboard

Which drugs does patent 6,689,761 protect, and when does it expire?

Patent 6,689,761 protects CRIXIVAN and is included in one NDA.

This patent has forty-one patent family members in thirty-five countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 6,689,761
Title: Combination therapy for HIV infection
Abstract:The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Inventor(s): Chodakewitz; Jeffrey A. (Gwynedd Valley, PA), Emini; Emilio A. (Paoli, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/382,113
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,689,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,689,761

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1160081 ➤ Try a Free Trial
Colombia 4700430 ➤ Try a Free Trial
Czech Republic 9702444 ➤ Try a Free Trial
Germany 69628819 ➤ Try a Free Trial
Denmark 0806957 ➤ Try a Free Trial
Algeria 1988 ➤ Try a Free Trial
Eurasian Patent Organization 000437 ➤ Try a Free Trial
Estonia 9700165 ➤ Try a Free Trial
Estonia 03514 ➤ Try a Free Trial
European Patent Office 0806957 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Deloitte
Julphar
Queensland Health
Johnson and Johnson
Cantor Fitzgerald
Merck
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot